Behavioural and psychological symptoms of dementia: GPs’ perspective on management

woman-65675_1920

Marie Crabbe presents the findings of a mixed-methods systematic review, which looks at General Practitioners’ knowledge, attitudes and experiences of managing behavioural and psychological symptoms of dementia.

[read the full story...]

Medical cannabis for mental illness: current use is not supported by research #MHQT

sharon-mccutcheon-798864-unsplash

As we prepare for our Cannabis #MHQT event on Wed 26 Sep, Luke Sheridan Rains dissects a narrative review that asks: Is cannabis treatment for anxiety, mood, and related disorders ready for prime time?

His answer is that current evidence does not support the use of medical cannabis for mental illnesses such as anxiety or depression.

[read the full story...]

Is Cannabidiol (CBD) an effective antipsychotic?

24281909498_a080b71a94_k

Luke Sheridan Rains publishes his debut blog on a recent multicentre RCT of Cannabidiol (CBD) as an adjunctive therapy for people with schizophrenia, which suggests that CBD had a beneficial, but modest impact on positive psychotic symptoms and severity of illness when used alongside existing antipsychotics.

[read the full story...]

Low dose Amisulpride for very late onset schizophrenia-like psychosis: the ATLAS study

kiwihug-393309-unsplash

Elwira Lubos summarises the recent ATLAS RCT of antipsychotic treatment for very late-onset schizophrenia-like psychosis, which provides evidence for the effectiveness of a very low dose of Amisulpride (100 mg).

[read the full story...]

“Where I End And You Begin”: A personal commentary on Russo’s ‘Through the eyes of the observed’ #PsychDrugDebate

Screen Shot 2018-07-23 at 12.59.20

Sarah Carr shares her own experiences of psychiatric medication and provides a critical reading of Jasna Russo’s new #PsychDrugDebate paper: ‘Through the eyes of the observed: re-directing the research on psychiatric drugs’.

[read the full story...]

How should we redirect research on psychiatric drugs? #PsychDrugDebate

image001-1

Alison Faulkner dissects the new McPin Foundation Talking Point Paper by Jasna Russo entitled: Through the eyes of the observed: re-directing research on psychiatric drugs.

Follow #PsychDrugDebate today on Twitter for further discussion about this vital issue.

[read the full story...]

Sexual function matters to people living with serious mental illness

bryan-apen-567698-unsplash

Rudiger Pittrof and Elana Covshoff from SHRINE (Sexual and Reproductive Health Rights, Inclusion and Empowerment) explore a recent review, which looks at the impact of severe mental disorders and psychotropic medications on sexual health and its implications for clinical management.

[read the full story...]

Polypharmacy for major depression: is practice evidence-based?

joshua-coleman-623077-unsplash

Jessica Bone reports on a recent cross-sectional study that looks at the clinical correlates of augmentation/combination treatment strategies in major depressive disorder.

[read the full story...]

Understanding the genetics of antipsychotic treatment response

simone-van-der-koelen-611419-unsplash

Marcus Munafo looks at a Chinese genome-wide association study that claims to have identified some of the genes associated with response to antipsychotic treatment.

[read the full story...]

Improving outcomes for people with first episode psychosis

ryan-holloway-261284-unsplash

Elwira Lubos summarises a recent review of reviews looking at the evidence for improving outcomes in first-episode psychosis.

[read the full story...]